B+
Bull case
30%
Probability
Target price
$19.00
+23.5% vs current
AUPH
AuriniaBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
AI scenario view
RankAlpha Sentiment CodexPost-earnings T+3Most likely
B
Base case
45%
Probability
Target price
$17.00
+10.5% vs current
B-
Bear case
25%
Probability
Target price
$13.00
-15.5% vs current
AI sentiment snapshot
Latest data as of 2026-05-14
Recent news sentiment (30D)
+0.2
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Sentiment proxy
+56.8
Score
AI commentary
Primary-source earnings tone was constructive, but near-term market interpretation appears more mixed than the headline beat alone suggests. Secondary market coverage around May 7-8, 2026 linked the initial weakness to guidance being reiterated rather than raised and to FY2026 revenue guidance sitting around prior consensus rather than above it. By the May 13, 2026 anchor of $16.03, that initial pressure appears to have partly reversed, but delayed analyst-revision evidence is still limited, so confidence should stay moderate rather than high.
RankAlpha Sentiment Codex - 2026-05-14
Open post-earnings memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-06-30catalystQ1 earnings beat with reiterated 2026 sales outlookMedium impact
Q1 results showed total revenue of $77.7M, LUPKYNIS net product sales of $73.6M, net income of $34.4M, diluted EPS of $0.25, and cash plus investments of $378.8M, while management reiterated 2026 total revenue guidance of $315M-$325M and net product sales guidance of $305M-$315M. The setup is constructive, but the lack of a guidance raise likely caps near-term upside despite solid execution. [#10-Q-2026-05-07]
2026-08-31eventKezar acquisition closes and shifts pipeline mixHigh impact
Aurinia completed the Kezar acquisition on May 8, 2026, with the merger closing on May 11, 2026 after roughly 80.24% of shares were tendered. That adds business-development optionality, but the market still needs evidence on integration discipline, capital allocation, and whether acquired assets can broaden Aurinia beyond LUPKYNIS dependence. [#8-K-2026-05-11]
2026-12-31catalystAritinercept and broader autoimmune pipeline need clinical de-riskingHigh impact
Management continues to position aritinercept as a growth platform, and the company has described it as being in clinical development across multiple potential autoimmune indications. That is the main longer-duration rerating path beyond the commercial LUPKYNIS base, but value realization still depends on trial execution, data quality, and regulatory progress rather than current revenue. [#10-K-2026-02-26]
Recommendation
N/A
No formal recommendation provided.
As of 2026-05-14 • Updated nightlySource: Internal modelMethodology